Effect of Social Media Support and Financial Incentives on PrEP Adherence

The Effect of Social Media Support and Financial Incentives on Adherence to HIV Pre-exposure Prophylaxis in Young MSM of Color in Washington, DC

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT03078153

Enrollment

Registered

2017-03-13

Start date

2017-04-01

Completion date

2020-12-15

Last updated

2021-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pre-Exposure Prophylaxis

Brief summary

The purpose of this study is to determine if social media support and financial incentives improve adherence to Truvada as PrEP in African American, Latino and Asian MSM aged 18 to 24 living in the Washington, DC area who are at high risk for HIV acquisition.

Interventions

BEHAVIORALFinancial Incentive

Participants will receive a $50 gift card at 3- and 6- month follow-up visits.

BEHAVIORALSocial Media Group

Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

MALE

Age

18 Years to 24 Years

Healthy volunteers

Yes

Inclusion criteria

* Male assigned at birth (regardless of current gender identity) * Age 18-24 * Black/African American, Latino or Asian * HIV negative * History of unprotected anal sex with a man in the last 6 months * Living within the DC metropolitan statistical area and anticipate remaining within the DC area for the next 6 months * Not enrolled in any other HIV prevention trial * Interested in taking PrEP * Not a current PrEP user and have not taken PrEP in the last 30 days * Able to provide informed consent

Exclusion criteria

* Female sex at birth * Age younger than 18 or older than 24 * Caucasian * HIV positive * Actively taking PrEP or having taken PrEP within 30 days of enrollment * Chronic hepatitis B infection * Known renal insufficiency * On probation or parole * Any other conditions that the Principal Investigator may consider a contraindication to enrolling in the study

Design outcomes

Primary

Measure	Time frame	Description
Adherence To Truvada	6 months	Level of Truvada drug levels inside red blood cells (performed by dried blood spots)

Secondary

Measure	Time frame	Description
New Cases of HIV	6 months	Number of reactive HIV rapid and 4th generation tests
Incidence of STIs	6 months	Positive RPR, oropharyngeal/rectal/penile chlamydia and gonorrhea during study

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026